Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.

Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):259-64. doi: 10.1038/pcan.2014.21. Epub 2014 Jun 24.

PMID:
24957547
[PubMed - in process]
2.

Current vaccination strategies for prostate cancer.

Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.

Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review.

PMID:
22001436
[PubMed - indexed for MEDLINE]
3.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
[PubMed - indexed for MEDLINE]
4.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis.

Kawalec P, Paszulewicz A, Holko P, Pilc A.

Arch Med Sci. 2012 Nov 9;8(5):767-75. doi: 10.5114/aoms.2012.31610. Epub 2012 Oct 8.

PMID:
23185184
[PubMed]
Free PMC Article
5.

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW.

Cancer. 2009 Aug 15;115(16):3670-9. doi: 10.1002/cncr.24429.

PMID:
19536890
[PubMed - indexed for MEDLINE]
Free Article
6.

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW.

Urology. 2013 Jun;81(6):1297-302. doi: 10.1016/j.urology.2013.01.061. Epub 2013 Apr 9.

PMID:
23582482
[PubMed - indexed for MEDLINE]
7.

The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.

Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.

Eur Urol. 2012 Apr;61(4):639-47. doi: 10.1016/j.eururo.2011.10.027. Epub 2011 Oct 24. Review.

PMID:
22036643
[PubMed - indexed for MEDLINE]
8.

Sipuleucel-T: in metastatic castration-resistant prostate cancer.

Plosker GL.

Drugs. 2011 Jan 1;71(1):101-8. doi: 10.2165/11206840-000000000-00000. Review.

PMID:
21175243
[PubMed - indexed for MEDLINE]
9.

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM.

J Clin Oncol. 2006 Jul 1;24(19):3089-94.

PMID:
16809734
[PubMed - indexed for MEDLINE]
10.

Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis.

Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, Reis RB.

Int Braz J Urol. 2012 Nov-Dec;38(6):717-27. Review.

PMID:
23302410
[PubMed - indexed for MEDLINE]
Free Article
11.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Di Lorenzo G, Ferro M, Buonerba C.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. Review.

PMID:
22177289
[PubMed - indexed for MEDLINE]
12.

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302).

Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F.

Eur Urol. 2014 Mar 6. pii: S0302-2838(14)00185-7. doi: 10.1016/j.eururo.2014.02.056. [Epub ahead of print]

PMID:
24647231
[PubMed - as supplied by publisher]
13.

Sipuleucel-T and immunotherapy in the treatment of prostate cancer.

Dawson NA, Roesch EE.

Expert Opin Biol Ther. 2014 May;14(5):709-19. doi: 10.1517/14712598.2014.896897. Epub 2014 Mar 12.

PMID:
24620782
[PubMed - in process]
14.

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

Sims RB.

Vaccine. 2012 Jun 19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.

PMID:
22122856
[PubMed - indexed for MEDLINE]
Free Article
15.

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.

Cancer Control. 2013 Jan;20(1):7-16. Review.

PMID:
23302902
[PubMed - indexed for MEDLINE]
Free Article
16.

Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.

Patel PH, Kockler DR.

Ann Pharmacother. 2008 Jan;42(1):91-8. Epub 2007 Dec 19. Review.

PMID:
18094343
[PubMed - indexed for MEDLINE]
18.

Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists.

Garcia JA.

Ther Adv Med Oncol. 2011 Mar;3(2):101-8. doi: 10.1177/1758834010397692.

PMID:
21789160
[PubMed]
Free PMC Article
19.

Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.

Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM.

Expert Rev Anticancer Ther. 2014 Jan;14(1):51-61. doi: 10.1586/14737140.2014.848065.

PMID:
24224900
[PubMed - in process]
20.

Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.

Gomella LG, Gelpi-Hammerschmidt F, Kundavram C.

Can J Urol. 2014 Apr;21(2 Supp 1):48-56.

PMID:
24775724
[PubMed - in process]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk